ANDA 90811, held by Hospira. Bivalirudin.
As of Nov 16, 2026, ANDA 90811 (Bivalirudin), held by Hospira, was first approved by FDA on Jul 14, 2015, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 14, 2015 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Bivalirudin250MG/VIAL · injectable;intravenous | Bivalirudin | Discontinued |
| Nov 22, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Nov 22, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 22, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 22, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jul 14, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters